A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
- Conditions
- Non-Hodgkin Lymphoma, B-cell
- Interventions
- Biological: CD19/CD20/BCMA CAR T cells
- Registration Number
- NCT06446128
- Lead Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
- Brief Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
- Detailed Description
This is a single arm, open-label, dose escalation investigator initiated (IIT) study, the primary objective is to evaluate the safety and tolerability of CD19/CD22/BCMA CAR-T therapy in patients with B cell non-Hodgkin lymphoma, and determine the maximum tolerated dose (MTD). For the secondary objectives, pharmacokinetics(PK), survival of CAR-T cells in vivo, pharmacodynamics (PD) and efficacy in R/R B cell NHL will be evaluated.
This study flow comprises of a screening phase( ≤28 days prior to apheresis), apheresis phase (occur upon enrollment, ≤10 days prior to infusion), lymphodepletion phase (from Day -5 to Day -3) ,infusion of CD19/CD22/BCMA CAR-T cells on Day0, DLT assessments phase from Day1 to Day 28 and post-treatment follow-up phase (Day 29 and up to end of the study).
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 20
-
Patients who are diagnosed with relapsed/refractory B cell non-Hodgkin lymphoma , especially
- Diffuse Large B Cell Lymphoma, not other specified (DLBCL,NOS),
- Primary Mediastinal Large B Cell Lymphoma (PMBCL)
- Transformation Follicular Lymphoma (TFL)
- High grade B-cell lymphoma(HGBCL)
- High grade B-cell lymphoma (HGBCL) with MYC(myelocytomatosis oncogene) and BCL2(B-cell lymphoma2) /BCL6 (B-cell lymphoma6) rearrangement
-
Refractory diseases are defined as one of the following
- No response to last line of therapy: i. Progressive disease (PD) as best response to most recent therapy regimen; ii. Stable disease (SD) as best response to most recent therapy regimen
- Not candidate for autologous stem cell transplant (ASCT) or refractory post-ASCT: i. Disease progression (PD) or relapsed ≤12 months of ASCT (must have biopsy proven recurrence in relapsed individuals) ii. If salvage therapy is given post-ASCT, the individual must have had no response to or relapsed after the last line of therapy
-
Individuals must have received adequate prior therapy including at a minimum:
- anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20-negative and
- an anthracycline containing chemotherapy regimen
-
Immunohistochemical staining shows at least two of B cell surface receptor antigen CD19,CD20, BCMA are positive(including weak, medium and strong positive)
-
At least one measurable lesion during the screening based on the recommendation for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma.
-
Life expectancy ≥ 12 weeks
-
Eastern cooperative oncology group (ECOG) performance status of 0 or 1
-
Adequate renal, hepatic, pulmonary and cardiac function defined as:
- Renal function: Serum creatinine ≤ 1.5 upper limit of normal(ULN), or eGFR ≥ 60 mL/min/1.73m2 [eGFR(estimated glomerular filtration rate)=186×age^-0.203×SCr^-1.154（mg/dl）,female×0.742]
- Hepatic function: i: Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 5 ULN and ii: total bilirubin ≤ 2 ULN, except in individuals with Gilbert syndrome (in Gilbert's syndrome patients, those with total bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN can be enrolled).iii: International normalized ratio (INR) or prothrombin time (PT) ≤1.5 ULN Pulmonary: Have the minimum level of pulmonary reserve, defined as ≤ CTCAE (Common Terminology Criteria for Adverse Events) grade 1 dyspnea and the SaO2(oxygen saturation)≥ 91% on room air
- Cardiac: left ventricular ejection fraction (LVEF) ≥50% determined by echocardiogram(ECG) or multigated acquisition scan (MUGA)
-
Adequate bone marrow function, define as:
- absolute neutrophil count (ANC) ≥1 ×10^9/L
- absolute lymphocyte count (ALC)≥ 0.5 ×10^9/L
- Platelets ≥50 ×109/L；
- Hemoglobulin ≥80 g/L; patients with bone marrow involvement can be enrolled if globulin>60 g/L
-
Female of child-bearing age and male participants must agree to use effective contraceptive methods until no CAR-T cells can be detected by PCR(polymerase chain reaction) test.
Key
-
Individuals who have antiCD45 or antiCD3 therapy
-
Individuals with detectable cerebrospinal fluid malignant cells, or brain metastases, or with a history of primary or secondary CNS (central nervous system) lymphoma, cerebrospinal fluid malignant cells or brain metastases
-
Presence or history of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement
-
History of allogeneic stem cell transplantation
-
Any of the following situations:
• HBsAg/ HBeAg positive; HBeAb/HBcAb positive and HBV(hepatitis B virus) DNA copies above the lower test limit;
-
HCV(hepatitis C virus) RNA positive
-
HIV(human immunodeficiency virus) positive or treponema pallidum positive
-
Presence of active or life-threatening fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management.
-
Individuals presence of unstable angina or myocardial infarction within 6 months of screening, or other severe/uncontrolled diseases during the screening (eg. Unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
-
Presence of uncontrolled arrhythmia with treatment
-
Pregnancy or breastfeeding women
Other protocol defined inclusion/exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description CD19/CD20/BCMA CAR T therapy CD19/CD20/BCMA CAR T cells The safety and tolerability of BZE2204 will be assessed in a "1+1+1+3" and "3+3" dose escalation approach in different B-cell non-hodgkin lymphoma
- Primary Outcome Measures
Name Time Method Dose-limiting toxicity(DLT) Day0-Day28 Safety
Maximum tolerated dose (MTD) Day0-Day28 Tolerability
- Secondary Outcome Measures
Name Time Method Maximum Plasma Concentration(Cmax) Day0-Day28，Day0-undetectable for CAR positive T cells Pharmacokinetics (PK)
Maximum Plasma Concentration Time (Tmax) Day0-Day28，Day0-undetectable for CAR positive T cells Pharmacokinetics (PK)
Area Under Curve (AUC) Day0-Day28，Day0-undetectable for CAR positive T cells Pharmacokinetics(PK)
Cytokines ( IL(interleukin)-2, IL-4, IL-6, IL-8, IL-10, IL-15, IFN(interferon)-γ, TNF(tumor necrosis factor)-α and MCP( monocyte chemoattractant protein)-1) Day0-Day28 Pharmacodynamics (PD)
Overall survival (OS) Day28,Month2,Month3,Month6,Month9,Month12,Month18,Month24 Clinical response assessed by Lugano Response Criteria for non-Hodgkin Lymphoma
CAR positive T cells Day0-Day28，Day0-undetectable for CAR positive T cells Pharmacokinetics(PK)
Progression-free survival (PFS) Day28,Month2,Month3,Month6,Month9,Month12,Month18,Month24 Clinical response assessed by Lugano Response Criteria for non-Hodgkin Lymphoma
Trial Locations
- Locations (1)
Mengchao Cancer Hospital
🇨🇳Shanghai, Shanghai, China